Class II — Potential Health Hazard

Potential health hazard — use of or exposure to this product may cause temporary or medically reversible adverse health consequences.

Zilretta (triamcinolone acetonide extended-release injectable suspension) Recalled by PACIRA PHARMACEUTICALS INC Due to Failed Dissolution Specifications - did not meet the...

Date: June 12, 2024
Company: PACIRA PHARMACEUTICALS INC
Status: Ongoing
Source: FDA (Drug)

What You Should Do

Stop using this product immediately. Do not consume, use, or distribute it.

Return the product to the place of purchase for a full refund. If you have questions, contact PACIRA PHARMACEUTICALS INC directly.

Affected Products

Zilretta (triamcinolone acetonide extended-release injectable suspension), 32 mg per vial, Rx only, Manufactured for: Pacira Pharmaceuticals Inc., San Diego, CA 92121, NDC 65250-003-01 (carton) NDC 65250-001-01 (vial) with Diluent 5 mL Sterile single-use vial, Rx Only, Mfd. for: Pacira Pharmaceuticals, Inc. NDC 65250-002-01

Quantity: 40,517 kits

Why Was This Recalled?

Failed Dissolution Specifications - did not meet the acceptance criteria for IVR Level 3 testing at 9 months 2-8¿C followed by 6 weeks at 25¿C

Where Was This Sold?

This product was distributed nationwide across all 50 states.

Affected (51 states)Not affected

About PACIRA PHARMACEUTICALS INC

PACIRA PHARMACEUTICALS INC has 2 total recalls tracked by RecallDetector.

Related Recalls

Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report